Conditions: Primary Aldosteronism Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Keywords: primary aldosteronism calcium channel blocker
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.

Detailed description:
BACKGROUND:

Primary aldosteronism is a common cause of hypertension. The cause of primary aldosteronism can be a unilateral aldosterone-producing adenoma (APA) or bilateral idiopathic hyperaldosteronism (IHA) whereby there is diffuse production of ectopic and non-physiologic aldosterone in the adrenal cortex. IHA likely contributes to the majority of all primary aldosteronism. Whereas surgical cure is the preferred therapy for APA, lifelong mineralocorticoid receptor antagonists (MRAs), such as spironolactone or eplerenone, are used to treat IHA. Treatment is important as patients with primary aldosteronism have an elevated risk of adverse cardiovascular and renal outcomes compared to patients with essential hypertension. It was long thought that curative surgery and lifelong medical therapy were equivalent treatment options, but more recent studies suggest that MRAs may not ameliorate the adverse cardiovascular and renovascular effects of primary aldosteronism to the same extent as surgery. For one, MRAs do not lower aldosterone levels, in fact, aldosterone levels are often increased with MRA therapy. Therefore, for IHA patients with primary aldosteronism in whom surgery is not an option, efforts to improve and optimize medical therapy are important.

Recent evidence in surgically removed adrenal glands from patients with primary aldosteronism and IHA has shown that even though IHA adrenal glands do not harbor adrenal tumors, they do harbor foci of ectopic aldosterone production and these foci are enriched for somatic mutations (gain of function) in CACNA1D, thereby suggesting that calcium channel mutations are predominant in the pathogenesis of IHA. This represents an intriguing target for medical therapy as blockade of this channel could lower intracellular calcium influx and hence decrease aldosterone production. Calcium channel blockade could also represent a more upstream therapy than mineralocorticoid receptor antagonists, which block the action of aldosterone at its receptor rather than lower its production.

This study is a pilot study to test the hypothesis that calcium channel blockade may lower autonomous aldosterone production in primary aldosteronism patients with IHA.

PROTOCOL:

Participants taking calcium channel blockers will be required to stop these medications for 2-4 weeks prior to initiation of the study. During this time, blood pressure will be managed with doxazosin and/or hydralazine to target an ideal range of \<130/80 mmHg, but practically ranges of 120-150/60-90 mmHg will be allowed. Serum potassium will be treated with supplemental potassium chloride to target a range of 3.5-4.5 mEq/L prior to initiation of the study. Participants already on a mineralocorticoid receptor blocker must have a plasma renin activity of \<1.0 ng/mL/h to participate, or be able to reduce or stop the dose of this medication for the duration of the study.

Study Visit 1: Participants will be provided sodium supplements (3g/daily) to take for five days prior to study visit 1. On the fifth day, a 24h urine collection will be obtained to measure urinary sodium and aldosterone and participants will arrive at the Clinical Research Center for testing. After one hour of seated rest, baseline blood measures will be obtained, and a single dose of amlodipine 10 mg will be administered. Blood measurements will be repeated every 2 hours to assess the serial change in outcome measures (t=2,4,and 6 hours after the amlodipine dose). Upon completion of the visit, participants will be prescribed amlodipine 10mg daily for 2 weeks.

Treatment phase: Following completion of Visit 1, participants will be prescribed amlodipine 10mg daily for 2 weeks. Home blood pressure monitoring will continue to ensure blood pressure remains in the target range of 120-150/80-90 mmHg. If blood pressure falls below this range with amlodipine, doxazosin and/or hydralazine doses may be reduced or stopped. If blood pressure remains low even after stopping doxazosin and hydralazine, the dose of amlodipine may be lowered to 5mg daily. Potassium chloride supplements may be titrated based on the values obtained at Study visit 1.

Study Visit 2: Participants will be provided sodium supplements (3g/daily) to take for five days prior to study visit 2. On the fifth day, a 24h urine collection will be obtained to measure urinary sodium and aldosterone and participants will arrive at the Clinical Research Center for testing. After one hour of seated rest, baseline blood measures will be obtained, and a single dose of amlodipine 10 mg will be administered. Blood measurements will be repeated every 2 hours to assess the serial change in outcome measures (t=2,4,and 6 hours after the amlodipine dose). Upon completion of the visit, the study will have concluded and participants will return to their usual care.

Arms:
arm 1: Amlodipine (dose 10 mg, once daily)

Interventions: intervention 1: Amlodipine
Intervention descriptions: intervention 1: Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks

Protocol document:
Prot_SAP_001.pdf: 
1 
 
 
 
Title: Calcium Channel Blockade in Primary Aldosteronism 
 
Detailed Protocol 
 
NCT04179019 
 
Date of IRB Approval & Document Version: 1/9/2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


2 
 
I. 
BACKGROUND AND SIGNIFICANCE 
 
Primary aldosteronism is the most common cause of secondary hypertension, with studies 
reporting prevalence rates of ~10% in the general hypertensive population and ~20% among 
patients with resistant hypertension. The cause of primary aldosteronism can be a unilateral 
aldosterone-producing adenoma (APA) or bilateral idiopathic hyperaldosteronism (IHA) whereby 
there is diffuse production of ectopic and non-physiologic aldosterone in the adrenal cortex.  IHA 
likely contributes to >70% of all primary aldosteronism. Whereas surgical cure is the preferred 
therapy for APA, lifelong mineralocorticoid receptor antagonists (MRAs), such as spironolactone 
or eplerenone, are used to treat IHA. Treatment is important as patients with primary 
aldosteronism have an elevated risk of adverse cardiovascular and renal outcomes compared to 
patients with essential hypertension. It was long thought that curative surgery and lifelong 
medical therapy were equivalent treatment options, but more recent studies suggest that MRAs 
may not ameliorate the adverse cardiovascular and renovascular effects of primary 
aldosteronism to the same extent as surgery. For one, MRAs do not lower aldosterone levels, in 
fact, aldosterone levels are even higher with MRA therapy. Therefore, for IHA patients with 
primary aldosteronism in whom surgery is not an option, efforts to improve and optimize medical 
therapy are important. 
 
In recent years, several mutations in cellular membrane ion channels and pumps have been found 
to cause primary aldosteronism. Nearly all APAs that cause primary aldosteronism harbor an 
underlying driver mutation in one or more of the following genes: KCNJ5 (inward-rectifying 
potassium channel), ATP1A1 (Na+/K+ ATPase), ATP2B3 (Ca2+ ATPase), CACNA1D (L-type 
voltage-dependent Ca2+ channel), CACNA1H (T-type voltage-dependent Ca2+ channel), or 
CLCN2 (chloride channel). The unifying mechanism of all these gene alterations is that the 
underlying pathology induces increased calcium ion influx into adrenal zona glomerulosa cells 
which induces excess aldosterone production.   
 
Moreover, recent evidence in surgically removed adrenal glands from patients with primary 
aldosteronism and IHA has shown that even though IHA adrenal glands do not harbor adrenal 
tumors, they do harbor foci of ectopic aldosterone production and these foci are enriched for 
mutations in CACNA1D, thereby suggesting that calcium channel mutations are predominant in 
the pathogenesis of IHA. This represents an intriguing target for medical therapy as blockade of 
this channel could lower intracellular calcium and hence decrease aldosterone production. 
Calcium channel blockade would also represent a more upstream therapy than mineralocorticoid 
receptor antagonists, which block aldosterone’s action at its receptor rather than lower its 
production. 
 
Calcium channel blockers such as amlodipine are a class of medications that have been used in 
the treatment of essential hypertension for years and are safe with minimal risks. We hypothesize 
that amlodipine can lower autonomous aldosterone production in primary aldosteronism patients 
with IHA, a population that is more likely to harbor a mutation in the L-type voltage-gated calcium 
channel and a population in whom medical therapy is usually the only treatment option. 
 
 
 
Preliminary Data to Support the Proposed Study 
 
 
II. 
SPECIFIC AIMS 
 


3 
 
The hypothesis for this pilot study is that the calcium-channel blocker amlodipine can 
specifically decrease aldosterone production in patients with idiopathic bilateral 
hyperaldosteronism. 
 
• Primary Outcome:  Change in 24-hour urinary aldosterone excretion rate and plasma 
aldosterone in response to maximal amlodipine therapy. 
 
•  Secondary Outcomes: Acute change in plasma aldosterone in response to amlodipine therapy.  
 
 
III. 
SUBJECT SELECTION 
 
Sample Size:  
 
Up to 15 participants with confirmed or presumed IHA will be recruited. Some patients with IHA 
will have this diagnosis confirmed via adrenal venous sampling. Many patients have not 
undergone adrenal venous sampling but have a preumptive diagnosis of IHA because they have 
no adrenal abnormalities on imaging and/or are already being treated with mineralocorticoid 
receptor antagonists. 
 
Participants will be included if they are aged 18-80 years, have a confirmed diagnosis of primary 
aldosteronism, a suppressed plasma renin activity (<1.0 ng/mL/h), and confirmed or presumed 
IHA. Participants taking a calcium-channel blocker will be included if they are willing to undergo 
a washout protocol (described below). Participants taking mineralocorticoid receptor antagonists 
will be included if their plasma renin activity is <1.0 ng/mL/h; if it is not, they may still be included 
if they are able to lower the dose of this medication such that their renin activity falls below 1.0 
ng/mL/h. 
 
Participants will be excluded if they have discrete or large bilateral adrenal adenomas on cross-
sectional imaging (done as a part of standard clinical care) to avoid including participants who 
may have APAs, which predominantly have KCNJ5 mutations rather than CACNA1D calcium 
channel mutations. Participants with anemia, leukopenia, or thrombocytopenia (based on our 
acceptable ranges) or a blood pressure greater than 180/100 mmHg, will be excluded. Pregnant 
or breastfeeding women will also be excluded. 
 
 
IV. 
SUBJECT ENROLLMENT 
 
The study will take place at Brigham and Women’s Hospital (BWH). Our research team has 
extensive experience and an established infrastructure for recruiting individuals with IHA. 
Participants will be recruited from 2 sources.  
 
1. Center for Adrenal Disorders at BWH: The PI sees primary aldosteronism patients in the 
clinic. In addition, participants undergoing adrenal venous sampling for primary 
aldosteronism will be contacted if they have IHA. Patients with IHA will be contacted 
regarding interest in participation by the PI’s research team with a letter.  
 
2. Partners Research Patient Data Registry (RPDR): The Brigham & Women’s Hospital 
and Partners affiliates i.e. Massachusetts General Hospital, Faulkner Hospital, Newton 
Wellesley, etc. have a shared database to identify potentially eligible patients that can be 
used for clinical research studies. We will search for patients with primary aldosteronism 


4 
 
in the RPDR and with IRB committee approval, conduct targeted chart reviews to assess 
which patients likely meet inclusion criteria for this study. Once we have identified 
potentially eligible patients, they will be invited to participate via the Mass General 
Brigham Patient Gateway secure online portal or we will identify their primary care 
physician, or endocrinologist, or other internist with close ties to the patient in our 
system, and request permission to contact their potentially eligible patient with our IRB 
approved letter (co-signed by the PI and physician) including information regarding the 
study. The letter is used to ask permission to send their patients a co-signed letter 
inviting them to learn more about and potentially participate in our study. In the letter, 
participants will be notified that we will be calling within about 2 weeks after receipt of the 
letter. Our phone number will be provided so individuals may contact us with questions 
or to opt out of receiving further information about the study. Interested patients will be 
invited for a screening visit to formally assess eligibility.  
 
V. 
STUDY PROCEDURES 
 
The study will take place in the outpatient clinical research centers of the BWH.  There will be one 
screening visit, and 3 study visits.  The duration of the entire study is 2-10 weeks (see protocol 
schema). 
 
 
 
 
Screening visit (Visit 1): Participants will meet with a study staff member (licensed physician or 
nurse practitioner or physician assistant) to review the study protocol, risks, and benefits.  They 
will have received the consent form ahead of this visit and it will be reviewed in detail and 
signed prior to proceeding. The screening visit will entail a brief review of the patient’s medical 
history, a physical examination, blood pressure measurements, an EKG will be perfomed, and 
phlebotomy to assess eligibility. Women between the ages of 18-50 will have a pregnancy test 
that must be negative. 
 
Blood pressure medication washout and optimization period: Many participants may already be 
treated with a calcium-channel blocker per standard of care. To assess the effect of amlodipine 
on aldosterone production, these participants will washout their prescribed calcium-channel 
blocker for 4-8 weeks and will have their blood pressure managed with other anti-hypertensive 
agents in the interim. After stopping their calcium-channel blocker, participants will be provided 
with a home blood pressure machine and taught how to measure their blood pressure at home 
and how to report daily readings to study staff.  The target blood pressure for this washout 
period, and throughout the entire study protocol, will be 120-150/60-90 mmHg. The upper limit 
of this blood pressure range exceeds the normal range because many patients with primary 
aldosteronism have chronically elevated and poorly controlled blood pressure; although study 
staff will make every effort to maintain their blood pressure in a normal range (<130/80 mmHg), 
CCB Drug 
Washout 
(if needed)
VISIT 2:  
Acute CCB Effect on 
Aldosterone Production
Objective - Can CCB acutely lower 
autonomous aldosterone secretion in PA?
VISIT 1:
SCREENING
Acute CCB 
Dose x1
Testing at 
T=0, 2, 4, 6 
hours
CCB 
therapy
x 2 weeks
Acute CCB 
Dose x1
Testing at 
T=0, 2, 4, 6 
hours
VISIT 3:  
Chronic CCB Effect on 
Aldosterone Production
Objective - Can CCB sustain reductions in 
autonomous aldosterone secretion in PA?


5 
 
this goal may not be achievable in this short study. If home blood pressure exceeds 130/80 
mmHg, participants will be prescribed doxazosin (in 2 mg daily increments up to 8 mg daily) 
and/or hydralazine (in 25 mg daily increments up to 25 mg three times daily) in efforts to keep 
blood pressure in the target range. These medications will be used to substitute calcium-
channel blockers since they do not interfere with the renin-angiotensin-aldosterone system and 
are the recommended medications by the international Endocrine Society guidelines. 
 
In addition to blood pressure monitoring during this washout period, serum potassium will be 
monitored to ensure it remains in a target range of 3.5-4.5 mEq/L. Most patients with primary 
aldosteronism are hypokalemic and already taking daily potassium supplements. Study staff 
may increase the dose of potassium supplementation (using potassium chloride in 20 mEq 
supplements) to keep serum potassium in the target range. Serum potassium will be checked at 
2-4 weeks, and if not in range, again at 4-8 weeks. 
 
Participants already taking a mineralocorticoid receptor antagonist (such as spironolactone or 
eplerenone) will be included and studied as long as their renin activity remains suppressed 
(<1.0 ng/mL/h). Participants who have a renin activity greater than or equal to 1.0 ng/mL/h while 
on mineralocorticoid receptor antagonists may still participate if their dose can be safely 
decreased such that renin activity decreases to <1.0 ng/mL/h. If needed, renin will be measured 
at 2-4 weeks, and if not in range, again at 4-8 weeks. 
 
This washout and optimization period will range from 4-8 weeks to provide sufficient time for 
optimization of washout, blood pressure, potassium, and renin levels.  Participants who are 
unable to tolerate a washout or maintain blood pressure or potassium in the target range, will be 
withdrawn from the study. 
 
Study Visit 2-Dexamethasone Suppression Test/Cosyntropin stimulation test: After completing 
the washout period, participants will be scheduled to undergo a dexamethasone suppression 
test and cosyntropin stimulation test. This will be conducted prior to the high sodium diet given 
before visit 3.  
 
The dexamethasone suppression test is often used in the clinical setting to measure whether 
there is excess cortisol secretion. Dexamethasone (1mg) is a synthetic adrenal steroid and is 
taken the night before the cosyntropin stimulation test between 11pm and 12am. When the 
participant arrives to the CCI the following morning between 8-9am, initial biochemical testing 
will include ACTH and cortisol levels. These hormone values will demonstrate how well cortisol 
can be suppressed.  
 
The cosyntropin stimulation test will measure how well cortisol can be stimulated. A cosyntropin 
stimulation test is a common procedure that is performed routinely in the ambulatory setting at 
BWH in the primary care, endocrine, and oncology clinics. It involves the measurement of 
adrenal hormones before, and one hour after, the administration of cosyntropin (an analogue of 
the peptide ACTH: “ACTH 1-24”). Participants will arrive to the CCI at 8-9am in the morning and 
will have an IV placed in the arm. A baseline blood measurement will be analyzed for cortisol, 
aldosterone, plasma renin activity, direct renin concentration, ACTH, and basic metabolic 
chemistries. The standard dose of cosyntropin (250 mcg) will then be administered by IV bolus 
and blood work for cortisol and aldosterone measured again 60mins later. This will conclude the 
visit which is expected to last ~2hours.   
 
Study Visits 3 and 4: Following screening and washout/optimization, there will be two study visits 
separated by 2 weeks (see Schema Figure). Critical determinants of aldosterone production 


6 
 
include body posture, dietary sodium intake, serum potassium, and blood pressure. Thus, this 
protocol ensures that all 4 of these confounders are controlled to ensure that outcome measures 
are reliable and reproducible. 
 
Study Visit 3: The objective for study visit 3 is to establish the magnitude of autonomous 
aldosterone production at baseline and evaluate the acute impact of amlodipine on aldosterone 
production.  
 
To ensure rigor and reproducibility, all aldosterone (and other measurements) will be conducted 
under conditions where diet and posture are controlled. Five days before study visit 3, participants 
will be provided with sodium supplements (in the form of 3 broth packets approximating 3,000 mg 
of sodium daily) to consume daily. The average daily sodium consumption in the United States is 
3.8-4.5 grams daily, and thus this sodium intake will ensure that all participants are consuming a 
typical U.S. sodium diet and for research purposes, ensure that the 24 hour urinary sodium 
excretion at study visit 3 is >200 mmol Na+/24h. This sodium loading is a standard of care clinical 
practice referred to as an “oral sodium suppression test” and the internationally recommended 
test to diagnose primary aldosteronism by the Endocrine Society. 
 
After consuming this sodium diet, participants will arrive at the BWH Clinical Research Center at 
8AM, after having collected their urine for 24 hours. An EKG will be performed if the participant 
had a remote screening visit. Participants will remain in an upright seated position for a total of 
seven hours. After one hour of seated rest, baseline blood measures will be obtained, and a single 
dose of amlodipine 10 mg will be administered. In order to reflect amlodipine pharmacodynamics, 
blood measurements will be repeated every 2 hours to assess the serial change in outcome 
measures (t=2,4,and 6 hours after the amlodipine dose). This serial blood testing may be 
performed via repeated venipuncture, or by placing an intravenous line to draw, whichever is 
preferable to the participant. Blood tests will include serum aldosterone, plasma renin activity, 
basic metabolic panel, adrenocorticotropic hormone, cortisol, and other hybrid adrenal steroids. 
Extra plasma and serum will be saved for future use and DNA will be extracted from peripheral 
leukocytes for genetic analyses of aldosterone-related genes. The 24h urine will be analyzed for 
aldosterone excretion rate, cortisol, sodium, potassium, and creatinine.  
 
During the study visit, participants will be able to drink water and after a 4-hour period be able to 
eat a light snack. After the study is completed, participants will be able to eat and encouraged to 
bring food with them for this. 
 
Treatment phase: Following completion of Visit 3, participants will be prescribed amlodipine 10mg 
daily for 2 weeks.  Home blood pressure monitoring will continue to ensure blood pressure 
remains in the target range of 120-150/80-90 mmHg.  If blood pressure falls below this range with 
amlodipine, doxazosin and/or hydralazine doses may be reduced or stopped.  If blood pressure 
remains low even after stopping doxazosin and hydralazine, the dose of amlodipine may be 
lowered to 5mg daily. Potassium chloride supplements may be titrated based on the values 
obtained at Study visit  3. 
 
Study Visit 4: The objective for study visit 4 is to establish the magnitude of autonomous 
aldosterone production after 2 weeks of amlodipine treatment. 
 
Participants will again complete 5 days of sodium supplements and arrive to the BWH Clinical 
Research Center at 8AM, bringing with them a 24-hour urine collection. Participants will be 
instructed to not take their daily amlodipine dose prior to arriving, they will take it as a part of the 
study visit. They will repeat the exact same study protocol completed at Visit 3. Participants will 


7 
 
remain in an upright seated position for a total of seven hours. After the first hour of seated rest, 
baseline blood measures will be obtained and a single dose of amlodipine (the dose will be the 
same dose they took for the preceding 2 weeks) will be administered. Blood and urinary 
measurements will again be performed exactly as they were at visit 3. 
 
 
VI. 
BIOSTATISTICAL ANALYSIS 
 
The analytic plan for this pilot study is to compare the change in plasma aldosterone (Aldo) and 
the change in 24h urinary aldosterone excretion rate (AER). The primary analytic plan will be to 
evaluate Aldo and AER between visit 2 and 3. Wilcoxon signed rank, or paired T-test statistics, 
will be used for univariate statistical analyses to assess significant differences between the paired 
measurements of Aldo and AER. Adjustment for potential confounders (age, sex, 
race/ethnicity, BMI, BP) will be considered using generalized linear mixed random effects models 
(SAS 9.4). Secondary analyses to assess the acute change in plasma aldosterone after a single 
dose of amlodipine will be conducted using the same methodological approach. 
 
Sample size calculations are based on an expected Aldo of 5 ng/dL, with up to a S.D. of 4-5 
ng/dL. It is thus estimated that 7-10 participants are needed in this paired design to reject the null 
hypothesis that ΔAldo does not significantly change with amlodipine therapy with 80% power. 
Similarly, for an expected AER of 7 mcg/24h, with a S.D. of 5-6 mcg/24h, it is estimated that 
6-8 participants are needed in this paired design to reject the null hypothesis that ΔAER does not 
significantly change with amlodipine therapy with 80% power.  
 
We aim to enroll 15 participants to provide sufficient sample size and power to detect differences 
even if 2-5 participants (up to 33%) are non-responders to amlodipine. As this is a pilot study, any 
information regarding the influence of amlodipine on aldosterone production may be useful in 
designing future studies. 
 
 
VII. 
RISKS AND DISCOMFORTS 
 
Sodium supplementation  
The sodium intake is not intrinsically harmful, and in fact contains a similar amount of sodium to 
the diet consumed by the average American. This sodium intake is also the standard of care, 
and international guideline recommended approach, to assess aldosterone production in 
patients with primary aldosteronism. Possible side effects include a rise in blood pressure or 
drop in serum potassium which study staff will be monitoring closely and will be able to titrate 
medications to prevent or treat. 
 
Risk of Washout Period/Risk of Stopping Regular Blood Pressure Medications 
During the washout/optimization period, there is a risk that the participants’ blood pressure may 
rise despite initiation of an alternative antihypertensive agent. Risks of high blood pressure 
include headache and in rare and extreme circumstances stroke, heart attack, and death. Home 
blood pressure will be closely monitored, and study staff will actively titrate alternative 
antihypertensive agent(s) to ensure blood pressure remains well-controlled. This is a commonly 
performed procedure in clinical practice and routine. 
 
Calcium channel blocker treatment (amlodipine) 


8 
 
Amlodipine is a commonly prescribed medication that has been used to treat essential 
hypertension for years. The most common side effect is swelling in the legs and ankles (which 
usually takes 1-2 weeks or longer to manifest). It can also cause low blood pressure particularly 
at a high dose, but this is unlikely in the current study. Other rare side effects include fluid in the 
lungs in heart failure patients, palpitations, fatigue, skin rash, and stomach upset. 
 
Hydralazine  
Hydralazine has been used for many years in the treatment of essential hypertension. It is an 
international guideline recommended medication for treatment in primary aldosteronism when 
diagnostic testing is conducted. Side effects include low blood pressure, fast heart rate, 
stomach upset, and headache. Rare side effects include an autoimmune lupus-like syndrome, 
liver damage, and decreased white blood cell count. It should not be used in patients with 
coronary artery disease. 
 
Doxazosin 
Doxazosin has been approved for the treatment of essential hypertension for many years. It is 
an international guideline recommended medication for treatment in primary aldosteronism 
when diagnostic testing is conducted. Side effects include low blood pressure, leg swelling, 
nausea, dizziness, and headache. Rare side effects include liver inflammation and angioedema 
(swelling of the lips and tongue).  
 
ACTH infusion 
Cosyntropin is a synthetic derivative of naturally occurring adrenocorticotrophic hormone 
(ACTH), specifically the first 24 of the 39 amino acids of the hormone. Very rarely, patients with 
a history of asthma or other forms of allergy may be predisposed to hypersensitivity reaction or 
anaphylaxis during Cosyntropin administration; bradycardia, tachycardia, hypertension, 
peripheral edema, and rash have also been reported with cosyntropin. A physician or nurse will 
be present for the test. This cosyntropin stimulation test is a common ambulatory test that is 
performed in the clinical setting.  
 
Dexamethasone 
Dexamethasone is a synthetic glucocorticoid. Very rarely dexamethasone may cause 
anaphylactic reactions in those with hypersensitivity to dexamethasone; infection; slow wound 
healing; diaphoresis; nausea; headache; and mood changes. Most of these reactions are cause 
from chronic use, not the one-time administration as in our study.  
 
 
Blood Draws/Phlebotomy 
Some may experience a mild sting or painful feeling at the site of needle or intravenous catheter 
insertion. Although uncommon, it can also lead to a blood clot or infection. Standard sterile 
precautions will be taken to minimize these risks.   
 
Pregnancy/Fetus 
Women cannot take part in this study if they are pregnant or breastfeeding. Women between 
the age of 18-50 years will be required to have a negative pregnancy test prior to taking part in 
the study. Women who are postmenopausal and amenorrheic for one year or who have had a 
surgical sterilization procedure are exempt from submitting to a pregnancy test. Women will be 
counseled about using abstinence or contraception during participation in this study to avoid 
exposure to potentially teratogenic medications. 
 
Genetic Information 


9 
 
Genetic information about this study does not have medical or treatment implications at this 
time. However, information about participation in a genetic study may influence insurance 
and/or employers. These risks are minimized by not sharing information about participation and 
by using de-identified study codes. We will not place genetic information in the medical record. 
All results and samples will be coded and the key to the code kept in a separate locked file.  
 
In order to allow researchers to share test results, the National Institutes of Health (NIH) and 
other central repositories have developed special data (information) banks that analyze data 
and collect the results of whole genome studies. These banks may also analyze and store DNA 
samples, as well. These central banks will store genetic information and samples and give them 
to other researchers to do more studies. Although it is impossible to predict how genetic 
information will be used in the future, there are many safeguards in place to ensure that all 
genetic information is protected and de-identified.  
 
Unknown Risks 
There may be other risks or side effects that are not known at this time.   
 
 
VIII. 
POTENTIAL BENEFITS 
 
Although patients are not expected to directly benefit from the trial, their participation will 
contribute to medical research. Because of the close monitoring, supervision, and pro-active 
blood pressure and potassium therapies, participants will likely see an improvement in their 
primary aldosteronism therapy goals, even though this is not the primary objective of the study.  
 
IX. 
REMUNERATION 
 
Patients will receive monetary compensation for participating in the study and parking and/or 
transportation costs will also be covered. Participants will receive $100 for completing study visit  
3 and $100 for completing study visit  4. Parking at BWH lots will be covered.  For participants 
who need transportation, reimbursement for public transportation and/or livery services (i.e. 
Uber, Lyft, taxi, etc) will be strongly considered on a case-by-case basis based on feasibility and 
location. 
 
X. 
MONITORING AND QUALITY ASSURANCE 
 
The Principal Investigator will be responsible for reviewing the safety and/or efficacy data and 
determining whether the research should be altered or stopped.   
 
Safety data will be reviewed on every case studied in the PI’s monthly research group meeting.  
The PI’s research group, the Cardiovascular Endocrinology Research Group (CERG), meets 
once a month on a Tuesday.  The CERG includes more than 5 patient-oriented clinical 
investigators who are all endocrinologists with detailed knowledge of human research protocols, 
safety monitoring, and managing hypertension.  At each CERG meeting, each PI presents 
recruitment status, adverse events/safety issues, minor deviations, and other pertinent study-
related issues to the group of PI’s. Research coordinators also attend this meeting.  Discussion 
of issues and a plan are formulated for each adverse event. The PI will be responsible for 
executing any plans agreed upon during these meetings. 
 
 
REFERENCES 


10 
 
1. Rossi GP, Barisa M, Belfiore A, et al. The aldosterone-renin ratio based on the plasma 
renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. 
Journal of hypertension 2010;28:1892-9. 
2. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, 
including surgically correctable forms, in centers from five continents. The Journal of clinical 
endocrinology and metabolism 2004;89:1045-50. 
3. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of 
patients with primary aldosteronism: an endocrine society clinical practice guideline. The 
Journal of clinical endocrinology and metabolism 2008;93:3266-81. 
4. Abdelhamid S, Muller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal 
Conn syndrome in hypertensive patients. Arch Intern Med 1996;156:1190-5. 
5. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary 
aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test 
among Italian hypertensives. Am J Hypertens 2002;15:896-902. 
6. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the 
prevalence of secondary hypertension among hypertensive patients visiting a general 
outpatient clinic in Japan. Hypertension research : official journal of the Japanese Society of 
Hypertension 2004;27:193-202. 
7. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary 
aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 
2006;48:2293-300. 
8. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary 
aldosteronism among unselected hypertensive patients: a prospective study based on the 
use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007;30:111-
7. 
9. Hannemann A, Bidlingmaier M, Friedrich N, et al. Screening for primary aldosteronism in 
hypertensive subjects: results from two German epidemiological studies. European journal 
of endocrinology / European Federation of Endocrine Societies 2012;167:7-15. 
10. Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary 
aldosteronism among patients with resistant hypertension in China. Journal of hypertension 
2013;31:1465-71; discussion 71-2. 
11. Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of 
Primary Aldosteronism Encountered in Primary Care Practice. Journal of the American 
College of Cardiology 2017;69:1811-20. 
12. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary 
aldosteronism in the Tayside hypertension clinic population. Journal of human hypertension 
2000;14:311-5. 
13. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of 
primary aldosteronism in 199 patients referred with hypertension. Clinical and experimental 
pharmacology & physiology 1994;21:315-8. 
14. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary 
aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin 
ratio. American journal of kidney diseases : the official journal of the National Kidney 
Foundation 2001;37:699-705. 
15. Williams D, Croal B, Furnace J, et al. The prevalence of a raised aldosterone-renin ratio 
(ARR) among new referrals to a hypertension clinic. Blood Press 2006;15:164-8. 
16. Williams JS, Williams GH, Raji A, et al. Prevalence of primary hyperaldosteronism in 
mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006;20:129-36. 
17. Westerdahl C, Bergenfelz A, Isaksson A, Wihl A, Nerbrand C, Valdemarsson S. High 
frequency of primary hyperaldosteronism among hypertensive patients from a primary care 
area in Sweden. Scand J Prim Health Care 2006;24:154-9. 


11 
 
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. 
Hyperaldosteronism among black and white subjects with resistant hypertension. 
Hypertension 2002;40:892-6. 
19. Benchetrit S, Bernheim J, Podjarny E. Normokalemic hyperaldosteronism in patients 
with resistant hypertension. Isr Med Assoc J 2002;4:17-20. 
20. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in 
resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-6. 
21. Nogueira AR, Bloch KV. Screening for primary aldosteronism in a cohort of Brazilian 
patients with resistant hypertension. J Clin Hypertens (Greenwich) 2008;10:619-23. 
22. Ribeiro MJ, Figueiredo Neto JA, Memoria EV, et al. Prevalence of primary 
hyperaldosteronism in a systemic arterial hypertension league. Arq Bras Cardiol 
2009;92:39-45. 
23. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ 
damage in primary aldosteronism compared with essential hypertension: a systematic 
review and meta-analysis. The lancet Diabetes & endocrinology 2018;6:41-50. 
24. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes 
and mortality in medically treated primary aldosteronism: a retrospective cohort study. The 
lancet Diabetes & endocrinology 2018;6:51-9. 
25. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of Atrial 
Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically 
Treated Primary Aldosteronism. JAMA cardiology 2018;3:768-74. 
26. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal Outcomes in 
Medically and Surgically Treated Primary Aldosteronism. Hypertension 2018;72:658-66. 
27. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results 
of the primary aldosteronismPY Study. Hypertension 2006;48:232-8. 
28. Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular 
filtration rate in primary aldosteronism. The Journal of clinical endocrinology and metabolism 
2009;94:869-75. 
29. Hundemer GL, Baudrand R, Brown JM, Curhan G, Williams GH, Vaidya A. Renin 
Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and 
Mineralocorticoid Receptor Activity. The Journal of clinical endocrinology and metabolism 
2017;102:1835-43. 
30. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with 
primary aldosteronism. Jama 2006;295:2638-45. 
31. Funder JW. Primary aldosteronism: clinical lateralization and costs. The Journal of 
clinical endocrinology and metabolism 2012;97:3450-2. 
32. Kupers EM, Amar L, Raynaud A, Plouin PF, Steichen O. A clinical prediction score to 
diagnose unilateral primary aldosteronism. The Journal of clinical endocrinology and 
metabolism 2012;97:3530-7. 
33. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. 
Hypertension 2007;50:447-53; discussion -53. 
34. Young MJ. Targeting the mineralocorticoid receptor in cardiovascular disease. Expert 
Opin Ther Targets 2013;17:321-31. 
35. Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular 
medicine. Integrated blood pressure control 2013;6:129-38. 
36. Ma TK, Szeto CC. Mineralocorticoid receptor antagonist for renal protection. Renal 
failure 2012;34:810-7. 
37. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and 
fibrosis. Nat Rev Nephrol 2013;9:459-69. 
38. Gilbert KC, Brown NJ. Aldosterone and inflammation. Current opinion in endocrinology, 
diabetes, and obesity 2010;17:199-204. 


12 
 
39. Carey RM. Aldosterone and cardiovascular disease. Current opinion in endocrinology, 
diabetes, and obesity 2010;17:194-8. 
40. Freel EM, Mark PB, Weir RA, et al. Demonstration of blood pressure-independent 
noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance 
imaging study. Circ Cardiovasc Imaging 2012;5:740-7. 
41. Stehr CB, Mellado R, Ocaranza MP, et al. Increased levels of oxidative stress, 
subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. 
Journal of hypertension 2010;28:2120-6. 
42. Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria 
and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. American 
journal of nephrology 2004;24:242-9. 
43. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with 
primary aldosteronism: a controlled cross-sectional study. Hypertension 2013;62:331-6. 
44. Milan A, Magnino C, Fabbri A, et al. Left heart morphology and function in primary 
aldosteronism. High blood pressure & cardiovascular prevention : the official journal of the 
Italian Society of Hypertension 2012;19:11-7. 
45. Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular 
events in patients with primary aldosteronism. The Journal of clinical endocrinology and 
metabolism 2013;98:4826-33. 
46. Young WF, Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and 
treatment. Endocrinology 2003;144:2208-13. 
47. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing 
adenomas and hereditary hypertension. Science 2011;331:768-72. 
48. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and 
ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature 
genetics 2013;45:440-4, 4e1-2. 
49. Azizan EAB, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D 
underlie a common subtype of adrenal hypertension. Nature genetics 2013;45:1055-60. 
50. Scholl UI, Goh G, Stolting G, et al. Somatic and germline CACNA1D calcium channel 
mutations in aldosterone-producing adenomas and primary aldosteronism. Nature genetics 
2013;45:1050-4. 
51. Scholl UI, Stolting G, Nelson-Williams C, et al. Recurrent gain of function mutation in 
calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. 
eLife 2015;4:e06315. 
52. Scholl UI, Stolting G, Schewe J, et al. CLCN2 chloride channel mutations in familial 
hyperaldosteronism type II. Nature genetics 2018. 
53. Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 
chloride channel gene causes primary aldosteronism. Nature genetics 2018. 
54. Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene 
expression in aldosterone-producing adenomas and adrenocortical cells. The Journal of 
clinical endocrinology and metabolism 2012;97:E1567-72. 
55. Monticone S, Hattangady NG, Penton D, et al. a Novel Y152C KCNJ5 mutation 
responsible for familial hyperaldosteronism type III. The Journal of clinical endocrinology 
and metabolism 2013;98:E1861-5. 
56. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE. 
Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone 
synthesis. Endocrinology 2012;153:1774-82. 
57. Williams TA, Monticone S, Schack VR, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 
Mutations in Aldosterone-Producing Adenomas. Hypertension 2014;63:188-95. 


13 
 
58. Tauber P, Aichinger B, Christ C, et al. Cellular Pathophysiology of an Adrenal Adenoma-
Associated Mutant of the Plasma Membrane Ca(2+)-ATPase ATP2B3. Endocrinology 
2016;157:2489-99. 
59. Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical 
correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 
2014;64:354-61. 
60. Sasano H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. 
Endocrine journal 1994;41:471-82. 
61. Omata K, Satoh F, Morimoto R, et al. Cellular and Genetic Causes of Idiopathic 
Hyperaldosteronism. Hypertension 2018;72:874-80. 
62. Nanba K, Chen AX, Omata K, et al. Molecular Heterogeneity in Aldosterone-Producing 
Adenomas. The Journal of clinical endocrinology and metabolism 2016;101:999-1007. 
63. Hattangady NG, Karashima S, Yuan L, et al. Mutated KCNJ5 activates the acute and 
chronic regulatory steps in aldosterone production. Journal of molecular endocrinology 
2016;57:1-11. 
64. Nanba K, Omata K, Tomlins SA, et al. Double adrenocortical adenomas harboring 
independent KCNJ5 and PRKACA somatic mutations. Eur J Endocrinol 2016;175:K1-6. 
65. Omata K, Yamazaki Y, Nakamura Y, et al. Genetic and Histopathologic Intertumor 
Heterogeneity in Primary Aldosteronism. J Clin Endocrinol Metab 2017;102:1792-6. 
66. Yamazaki Y, Nakamura Y, Omata K, et al. Histopathological Classification of Cross-
Sectional Image-Negative Hyperaldosteronism. The Journal of clinical endocrinology and 
metabolism 2017;102:1182-92. 
67. Nanba AT, Nanba K, Byrd JB, et al. Discordance between imaging and 
immunohistochemistry in unilateral primary aldosteronism. Clinical endocrinology 
2017;87:665-72. 
68. Nanba K, Omata K, Else T, et al. Targeted Molecular Characterization of Aldosterone-
Producing Adenomas in White Americans. J Clin Endocrinol Metab 2018;103:3869-76. 
69. Nanba K, Omata K, Gomez-Sanchez CE, et al. Genetic Characteristics of Aldosterone-
Producing Adenomas in Blacks. Hypertension 2019:HYPERTENSIONAHA11812070. 
70. Lerario AM, Nanba K, Blinder AR, et al. Genetics of aldosterone-producing adenomas 
with pathogenic KCNJ5 variants. Endocrine-related cancer 2019. 
71. Nanba K, Vaidya A, Williams GH, Zheng I, Else T, Rainey WE. Age-Related 
Autonomous Aldosteronism. Circulation 2017;136:347-55. 
72. Omata K, Anand SK, Hovelson DH, et al. Aldosterone-Producing Cell Clusters 
Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals. J 
Endocr Soc 2017;1:787-99. 
73. Sun N, Wu Y, Nanba K, et al. High-Resolution Tissue Mass Spectrometry Imaging 
Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. Endocrinology 
2018;159:1511-24. 
74. Omata K, Tomlins SA, Rainey WE. Aldosterone-Producing Cell Clusters in Normal and 
Pathological States. Horm Metab Res 2017;49:951-6. 
75. Nanba K, Vaidya A, Rainey WE. Aging and Adrenal Aldosterone Production. 
Hypertension 2018;71:218-23. 
76. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with 
nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012;59:235-40. 
77. Meyer LS, Wang X, Susnik E, et al. Immunohistopathology and Steroid Profiles 
Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary 
Aldosteronism. Hypertension 2018;72:650-7. 
78. Stindl J, Tauber P, Sterner C, Tegtmeier I, Warth R, Bandulik S. Pathogenesis of 
Adrenal Aldosterone-Producing Adenomas Carrying Mutations of the Na(+)/K(+)-ATPase. 
Endocrinology 2015;156:4582-91. 


14 
 
79. Xie CB, Shaikh LH, Garg S, et al. Regulation of aldosterone secretion by Cav1.3. 
Scientific reports 2016;6:24697. 
80. Wang T, Satoh F, Morimoto R, et al. Gene expression profiles in aldosterone-producing 
adenomas and adjacent adrenal glands. European journal of endocrinology / European 
Federation of Endocrine Societies 2011;164:613-9. 
81. Nogueira EF, Gerry D, Mantero F, Mariniello B, Rainey WE. The role of TASK1 in 
aldosterone production and its expression in normal adrenal and aldosterone-producing 
adenomas. Clinical endocrinology 2010;73:22-9. 
82. Bassett MH, Mayhew B, Rehman K, et al. Expression profiles for steroidogenic enzymes 
in adrenocortical disease. The Journal of clinical endocrinology and metabolism 
2005;90:5446-55. 
83. Felizola SJ, Nakamura Y, Ono Y, et al. PCP4: a regulator of aldosterone synthesis in 
human adrenocortical tissues. Journal of molecular endocrinology 2014. 
84. Bird IM, Hanley NA, Word RA, et al. Human NCI-H295 adrenocortical carcinoma cells: a 
model for angiotensin-II-responsive aldosterone secretion. Endocrinology 1993;133:1555-
61. 
85. Rainey WE, Bird IM, Mason JI. The NCI-H295 cell line: a pluripotent model for human 
adrenocortical studies. Molecular and cellular endocrinology 1994;100:45-50. 
86. Wang T, Rowland JG, Parmar J, Nesterova M, Seki T, Rainey WE. Comparison of 
aldosterone production among human adrenocortical cell lines. Hormone and metabolic 
research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2012;44:245-
50. 
87. Xing Y, Parker CR, Edwards M, Rainey WE. ACTH is a potent regulator of gene 
expression in human adrenal cells. Journal of molecular endocrinology 2010;45:59-68. 
88. Xing Y, Edwards MA, Ahlem C, et al. The effects of ACTH on steroid metabolomic 
profiles in human adrenal cells. The Journal of endocrinology 2011;209:327-35. 
89. Xing Y, Rainey WE, Apolzan JW, Francone OL, Harris RB, Bollag WB. Adrenal cell 
aldosterone production is stimulated by very-low-density lipoprotein (VLDL). Endocrinology 
2012;153:721-31. 
90. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The orphan nuclear receptors 
NURR1 and NGFIB regulate adrenal aldosterone production. Molecular endocrinology 
2004;18:279-90. 
91. Bassett MH, White PC, Rainey WE. A role for the NGFI-B family in adrenal zonation and 
adrenocortical disease. Endocrine research 2004;30:567-74. 
92. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. 
Molecular and cellular endocrinology 2004;217:67-74. 
93. Clyne CD, Nguyen A, Rainey WE. The effects of KN62, a Ca2+/calmodulin-dependent 
protein kinase II inhibitor, on adrenocortical cell aldosterone production. Endocrine research 
1995;21:259-65. 
94. Clyne CD, White PC, Rainey WE. Calcium regulates human CYP11B2 transcription. 
Endocrine research 1996;22:485-92. 
95. Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC, Rainey WE. Angiotensin II and 
potassium regulate human CYP11B2 transcription through common cis-elements. Molecular 
endocrinology 1997;11:638-49. 
96. Condon JC, Pezzi V, Drummond BM, Yin S, Rainey WE. Calmodulin-dependent kinase I 
regulates adrenal cell expression of aldosterone synthase. Endocrinology 2002;143:3651-7. 
97. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of 
aldosterone production. Molecular and cellular endocrinology 2012;350:151-62. 
98. Nogueira EF, Rainey WE. Regulation of aldosterone synthase by activator transcription 
factor/cAMP response element-binding protein family members. Endocrinology 
2010;151:1060-70. 


15 
 
99. Nogueira EF, Vargas CA, Otis M, Gallo-Payet N, Bollag WB, Rainey WE. Angiotensin-II 
acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells. J 
Mol Endocrinol 2007;39:365-74. 
100. 
Nogueira EF, Xing Y, Morris CA, Rainey WE. Role of angiotensin II-induced rapid 
response genes in the regulation of enzymes needed for aldosterone synthesis. Journal of 
molecular endocrinology 2009;42:319-30. 
101. 
Pezzi V, Clark BJ, Ando S, Stocco DM, Rainey WE. Role of calmodulin-
dependent protein kinase II in the acute stimulation of aldosterone production. The Journal 
of steroid biochemistry and molecular biology 1996;58:417-24. 
102. 
Pezzi V, Clyne CD, Ando S, Mathis JM, Rainey WE. Ca(2+)-regulated expression 
of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein 
kinases. Endocrinology 1997;138:835-8. 
103. 
Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative 
genomics. Nature biotechnology 2018;36:46-60. 
104. 
Zheng S, Cherniack AD, Dewal N, et al. Comprehensive Pan-Genomic 
Characterization of Adrenocortical Carcinoma. Cancer cell 2016;29:723-36. 
105. 
Rege J, Nishimoto HK, Nishimoto K, Rodgers RJ, Auchus RJ, Rainey WE. Bone 
Morphogenetic Protein-4 (BMP4): A Paracrine Regulator of Human Adrenal C19 Steroid 
Synthesis. Endocrinology 2015;156:2530-40. 
106. 
Rege J, Karashima S, Lerario AM, et al. Age-dependent Increases in Adrenal 
Cytochrome b5 and Serum 5-Androstenediol-3-sulfate. The Journal of clinical endocrinology 
and metabolism 2016;101:4585-93. 
107. 
Nakamura Y, Rege J, Satoh F, et al. Liquid chromatography-tandem mass 
spectrometry analysis of human adrenal vein corticosteroids before and after 
adrenocorticotropic hormone stimulation. Clinical endocrinology 2012;76:778-84. 
108. 
Tauber P, Penton D, Stindl J, et al. Pharmacology and pathophysiology of 
mutated KCNJ5 found in adrenal aldosterone-producing adenomas. Endocrinology 
2014;155:1353-62. 
109. 
Funder JW, Carey RM, Mantero F, et al. The Management of Primary 
Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical 
Practice Guideline. The Journal of clinical endocrinology and metabolism 
2016;101:jc20154061. 
110. 
Vaidya A, Malchoff CD, Auchus RJ, Committee AAS. An Individualized Approach 
to the Evaluation and Management of Primary Aldosteronism. Endocr Pract 2017;23:680-9. 
111. 
Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A. Incidence of Atrial 
Fibrillation and Mineralocorticoid Receptor Activity in Patients with Medically and Surgically 
Treated Primary Aldosteronism. JAMA Cardiology 2018;3:768-74. 
112. 
Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A. Renal Outcomes in 
Medically Treated Primary Aldosteronism. Hypertension 2018;72:658-66. 
113. 
Wu VC, Chueh SJ, Chen L, et al. Risk of new-onset diabetes mellitus in primary 
aldosteronism: a population study over 5 years. J Hypertens 2017;35:1698-708. 
114. 
Wu VC, Wang SM, Chang CH, et al. Long term outcome of Aldosteronism after 
target treatments. Sci Rep 2016;6:32103. 
115. 
Omata K, Satoh F, Morimoto R, et al. Cellular and Genetic Causes of Idiopathic 
Hyperaldosteronism. Hypertension 2018;in press, epub ahead of print. 
116. 
Kline GA, Darras P, Leung AA, So B, Chin A, Holmes DT. Surprisingly low 
aldosterone levels in peripheral veins following intravenous sedation during adrenal vein 
sampling: implications for the concept of nonsuppressibility in primary aldosteronism. J 
Hypertens 2019;37:596-602. 


16 
 
117. 
Kowarski A, de Lacerda L, Migeon CJ. Integrated concentration of plasma 
aldosterone in normal subjects: correlation with cortisol. J Clin Endocrinol Metab 
1975;40:205-10. 
118. 
Nadler JL, Hsueh W, Horton R. Therapeutic effect of calcium channel blockade in 
primary aldosteronism. J Clin Endocrinol Metab 1985;60:896-9.